drugset / Trial / NCT07087158
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.
Timeline
- Start
- 2025-09-08
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBR854 | Unknown | 9e+09 cells | Intravenous |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |